8-K: Serina Responds to FDA Hold on Parkinson's Drug SER-252

Serina Therapeutics submitted a complete response to the FDA's clinical hold letter for its lead Parkinson's disease program, SER-252, targeting first-patient-in for Q1 2026.

Summary

• Serina Therapeutics, Inc. submitted a complete response to the U.S. Food and Drug Administration's (FDA) clinical hold letter for its lead Investigational New Drug (IND) candidate, SER-252, for advanced Parkinson's disease.
• The FDA had placed a full clinical hold on the SER-252 IND application on November 25, 2025, pending additional information related to a commonly used formulation excipient, trehalose.
• The issues identified by the FDA do not relate to the apomorphine active drug substance, its mechanism of action, the use of the enFuse device, or the broader 505(b)(2) NDA development pathway.
• Serina's complete response, submitted on December 9, 2025, includes a detailed data package supporting the proposed use of trehalose as a subcutaneous excipient and a revised protocol to initiate the single ascending dose (SAD) phase.
• The company anticipates initiating the SAD phase of the SER-252-1b trial and achieving first-patient-in (FPI) in Q1 2026, subject to timely resolution of the clinical hold and customary regulatory and ethics approvals.
• Global site start-up and regulatory activities are continuing in Australia and other regions as part of the registrational program, despite the clinical hold.

Sentiment

Score: 4

Explanation: The clinical hold is a negative event, causing a delay in the program. However, the company has promptly responded, and the FDA's concerns are limited to an excipient rather than the core drug substance or mechanism of action, which mitigates some of the severity. The continued global site activities show preparedness.

Positives

• Serina Therapeutics has submitted a complete and thorough response to the FDA's clinical hold letter, demonstrating proactive engagement with the regulatory body.
• The FDA's concerns are specifically related to a formulation excipient (trehalose) and do not involve the active drug substance (apomorphine), its mechanism of action, or the delivery device (enFuse), which are fundamental aspects of the therapy.
• The company is continuing global site start-up and regulatory activities in Australia and other regions, indicating preparedness to advance the program once the hold is lifted.

Negatives

• The SER-252 program for advanced Parkinson's disease is currently under a full clinical hold by the FDA, preventing the initiation of the planned Phase 1b registrational study.
• The clinical hold has resulted in a delay, with the first-patient-in for the Phase 1b study now targeted for Q1 2026, subject to FDA feedback, which was likely anticipated earlier.

Risks

• The timing and extent of the FDA's review of Serina's response and the decision to lift the clinical hold are uncertain.
• Inherent uncertainties in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates, and/or launch dates.
• The possibility of unfavorable new clinical data and further analyses of existing clinical data.
• Serina's ability to continue as a going concern.
• The risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities.
• Whether regulatory authorities will be satisfied with the design of and results from clinical studies.
• Whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions.
• Whether and when regulatory authorities may approve any potential applications, which depends on factors like product benefits outweighing risks and determination of efficacy.
• If approved, whether any such drug or vaccine candidates will be commercially successful.
• Decisions by regulatory authorities impacting labeling, manufacturing processes, safety, and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates.
• Competitive developments in the pharmaceutical industry.

Future Outlook

Serina Therapeutics aims to initiate the single ascending dose (SAD) phase of the SER-252-1b trial and achieve first-patient-in (FPI) in Q1 2026, contingent on the FDA lifting the clinical hold. The company will continue global site start-up and regulatory activities. Serina also intends to advance additional applications of its proprietary POZ platform via out-licensing, co-development, or other partnership arrangements, building on its non-exclusive license agreement with Pfizer, Inc.

Management Comments

• "Our priority has been to respond thoroughly and constructively to the FDAs requests. We believe our submission directly addresses the FDAs questions on trehalose, and we appreciate the Agencys continued engagement as we work toward initiating the registrational SER-252-1b trial." Steve Ledger, Chief Executive Officer of Serina Therapeutics.

Industry Context

Serina Therapeutics operates as a clinical-stage biotechnology company focused on neurological diseases, particularly Parkinson's disease. The company leverages its proprietary POZ Platform™ drug optimization technology to improve drug profiles. The regulatory process, including FDA clinical holds, is a common and critical hurdle in the biotechnology industry, often impacting development timelines and investor sentiment. The 505(b)(2) NDA development pathway mentioned suggests a strategy to leverage existing safety and efficacy data of an approved drug (apomorphine) while developing a new formulation, a common approach to accelerate drug development.

Stakeholder Impact

• Shareholders: Potential for increased volatility in share price due to the uncertainty surrounding the FDA's decision on the clinical hold and the delay in the program. Positive resolution could lead to a price increase, while further delays or negative feedback could lead to a decrease.
• Patients with advanced Parkinson's disease: The delay in the SER-252 clinical trial means a longer wait for a potential new treatment option.
• Employees: Continued work on the SER-252 program and global site activities, but with the pressure of regulatory review.

Next Steps

• FDA review of Serina's complete response to the clinical hold letter.
• Resolution of the clinical hold by the FDA.
• Initiation of the single ascending dose (SAD) phase of the SER-252-1b trial in Q1 2026.
• Achieving first-patient-in (FPI) for the registrational Phase 1b study in Q1 2026.
• Obtaining customary regulatory and ethics approvals for the trial.

Key Dates

Recommendation

The clinical hold on SER-252 introduces significant uncertainty and a delay in the program's timeline. While Serina Therapeutics has submitted a complete response addressing the FDA's concerns regarding an excipient, the timing and outcome of the FDA's review are unknown. The fact that the core drug substance and mechanism of action are not implicated is a positive, suggesting the issue may be resolvable. However, until the clinical hold is officially lifted and the trial can proceed, a cautious 'hold' recommendation is warranted for investors, as the stock's performance will largely depend on the regulatory outcome.

Keywords

Serina Therapeutics, SER-252, Parkinson's disease, FDA clinical hold, biotechnology, drug development, POZ Platform, trehalose, apomorphine, clinical trial, regulatory update